Marta Giovanetti, Vagner Fonseca, Eduan Wilkinson, Houriiyah Tegally, Emmanuel James San, Christian L Althaus, Joilson Xavier, Svetoslav Nanev Slavov, Vincent Louis Viala, Alex Ranieri Jerônimo Lima, Gabriela Ribeiro, Jayme A Souza-Neto, Heidge Fukumasu, Luiz Lehmann Coutinho, Rivaldo Venancio da Cunha, Carla Freitas, Carlos F Campelo de A e Melo, Wildo Navegantes de Araújo, Rodrigo Fabiano Do Carmo Said, Maria Almiron, Tulio de Oliveira, Sandra Coccuzzo Sampaio, Maria Carolina Elias, Dimas Tadeu Covas, Edward C Holmes, José Lourenço, Simone Kashima, Luiz Carlos Junior de Alcantara, Inst Oswaldo Cruz, Universidade Federal de Minas Gerais (UFMG), Univ Campus Biomed Roma, Organizacao Pan Amer Saude, Univ KwaZulu Natal, Stellenbosch Univ, Univ Bern, Fundacao Ezequiel Dias, Universidade de São Paulo (USP), Butantan Inst, Universidade Estadual Paulista (UNESP), Fundacao Oswaldo Cruz, Coordenacao Geral Labs Saude Publ, Univ Washington, Univ Oxford, Univ Sydney, and Univ Lisbon
Made available in DSpace on 2022-04-28T17:21:53Z (GMT). No. of bitstreams: 0 Previous issue date: 2022-04-01 National Institutes of Health USA CRP-ICGEB RESEARCH GRANT 2020 Project Oswaldo Cruz Foundation Brazilian Ministry of Health Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) European Union's Horizon 2020 research and innovation programme-project EpiPose South African Department of Science and Innovation South African Medical Research Council under the BRICS JAF Australian Research Council Laureate Fellowship The coronavirus disease 2019 (COVID-19) epidemic in Brazil was driven mainly by the spread of Gamma (P.1), a locally emerged variant of concern (VOC) that was first detected in early January 2021. This variant was estimated to be responsible for more than 96 per cent of cases reported between January and June 2021, being associated with increased transmissibility and disease severity, a reduction in neutralization antibodies and effectiveness of treatments or vaccines, and diagnostic detection failure. Here we show that, following several importations predominantly from the USA, the Delta variant rapidly replaced Gamma after July 2021. However, in contrast to what was seen in other countries, the rapid spread of Delta did not lead to a large increase in the number of cases and deaths reported in Brazil. We suggest that this was likely due to the relatively successful early vaccination campaign coupled with natural immunity acquired following prior infection with Gamma. Our data reinforce reports of the increased transmissibility of the Delta variant and, considering the increasing concern due to the recently identified Omicron variant, argues for the necessity to strengthen genomic monitoring on a national level to quickly detect the emergence and spread of other VOCs that might threaten global health. Inst Oswaldo Cruz, Lab Flavivirus, Fundacao Aswaldo Cruz, FIOCRUZ,IOC, Av Brasil 4365, BR-21040360 Rio De Janeiro, RJ, Brazil Univ Fed Minas Gerais, Inst Ciencias Biol, Lab Genet Celular & Mol, Av Pres Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil Univ Campus Biomed Roma, Dept Sci & Technol Humans & Environm, Via Alvaro Portillo 21, I-00128 Rome, Italy Organizacao Pan Amer Saude, Organizacao Mundial Saude, Lote 19 Ave Nacoes, BR-70312970 Brasilia, DF, Brazil Univ KwaZulu Natal, Coll Hlth Sci, Sch Lab Med & Med Sci, KwaZulu Natal Res Innovat & Sequencing Platfom KR, 238 Mazisi Kunene Rd, ZA-4041 Durban, South Africa Stellenbosch Univ, Ctr Epidem Response & Innovat CERI, Sch Data Sci & Computat Thinking, Banhoek Rd & Joubert St, ZA-7600 Stellenbosch, South Africa Univ Bern, Inst Social & Prevent Med, Hochschulstr 6, CH-3012 Bern, Switzerland Fundacao Ezequiel Dias, Lab Cent Saude Publ Estado Minas Gerais, Rua Conde Pereira Carneiro,80 Gameleira, BR-30510010 Belo Horizonte, MG, Brazil Univ Sao Paulo, Blood Ctr Ribeirao Preto, Ribeirao Preto Med Sch, R Quintino Bocaiuva 470, BR-14015160 Ribeirao Preto, SP, Brazil Butantan Inst, Ave Doutor Vital Brasil 1500, Sao Paulo, SP, Brazil Sao Paulo State Univ UNESP, Sch Agr Sci, R Quintino Bocaiuva 470, BR-05508900 Botucatu, SP, Brazil Univ Sao Paulo, Sch Anim Sci & Food Engn, Dept Vet Med, R Quintino Bocaiuva 470, Sao Paulo, Brazil Univ Sao Paulo, Ctr Genom Func ESALQ, R Quintino Bocaiuva 470, Piracicaba, SP, Brazil Fundacao Oswaldo Cruz, Biomanguinhos, Av Brasil 4365, BR-21040360 Rio De Janeiro, RJ, Brazil Coordenacao Geral Labs Saude Publ, Minist Saude CGLAB SVS MS, Secretaria Vigilancia Saude, Esplanada Ministerios Bloco G Edificio Sede, BR-70058900 Brasilia, DF, Brazil Univ KwaZulu Natal, Ctr AIDS Programme Res South Africa CAPRISA, Doris Duke Med Res Inst, Nelson R Mandela Sch Med, Private Bag X7, ZA-4013 Congella, South Africa Univ Washington, Dept Global Hlth, Schmitz Hall 1410 NE Campus Pkway Box 355852, Seattle, WA 98195 USA Univ Oxford, Dept Zool, Peter Medawar Bldg,1a Mansfield Rd, Oxford, England Univ Sydney, Sch Life & Environm Sci, Sydney Inst Infect Dis, Sydney, NSW, Australia Univ Sydney, Sch Med Sci, Sydney, NSW, Australia Univ Lisbon, Biosyst & Integrat Sci Inst BioISI, P-1749016 Lisbon, Portugal Sao Paulo State Univ UNESP, Sch Agr Sci, R Quintino Bocaiuva 470, BR-05508900 Botucatu, SP, Brazil National Institutes of Health USA: U01 AI151698 CRP-ICGEB RESEARCH GRANT 2020 Project: CRP/BRA20-03 CRP-ICGEB RESEARCH GRANT 2020 Project: CRP/20/03 Oswaldo Cruz Foundation: VPGDI-027-FIO-20-2-2-30 Brazilian Ministry of Health: SCON2021-00180 CNPq: 426559/2018-5 FAPERJ: E-26/202.930/2016 FAPERJ: E-26/202.248/2018(238504) FAPERJ: E26/202.665/2019(247400) European Union's Horizon 2020 research and innovation programme-project EpiPose: 101003688 South African Medical Research Council under the BRICS JAF: 2020/049 Australian Research Council Laureate Fellowship: FL170100022